Elagolix dosage and impact on endometriosis
article
OA: closed
CC0
AI-generated summary
Elagolix at two different dosages effectively reduced dysmenorrhea and nonmenstrual pelvic pain in women with endometriosis, building on prior findings of its estrogen-suppressing capabilities.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
New research on two different dosages of elagolix show that both doses improved dysmenorrhea and nonmenstrual pelvic pain in women with endometriosis. The findings, published in NEJM, add to data from previous studies of the drug, which showed that it produced partial to nearly full estrogen suppression.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK